Clinical trial • Phase III • Respiratory | Other

LEBRIKIZUMAB for Chronic rhinosinusitis with nasal polyps

Phase III trial of LEBRIKIZUMAB for Chronic rhinosinusitis with nasal polyps.

Overview

Trial Therapeutic Area
Respiratory | Other
Trial Disease
Chronic rhinosinusitis with nasal polyps
Trial Stage
Phase III
Drug Modality
Monoclonal antibody | Small molecule
Paediatric Trial
Yes

Key dates

Initial CTIS Submission Date
12-04-2024
First CTIS Authorization Date
30-07-2024

Trial design

Randomised, placebo for lebrikizumab (matching placebo arm). background intranasal corticosteroid (mometasone furoate nasal spray) used as background therapy. specific lebrikizumab dose and schedule not specified in the provided data.-controlled Phase III trial in Spain, Hungary, Belgium and others.

Randomised
Yes
Comparator
Placebo for Lebrikizumab (matching placebo arm). Background intranasal corticosteroid (mometasone furoate nasal spray) used as background therapy. Specific lebrikizumab dose and schedule not specified in the provided data.
Target Sample Size
748
Trial Duration For Participant
168

Eligibility

Recruits 748 paediatric patients.

Pregnancy Exclusion
11. Female participant who is pregnant, breastfeeding, or is planning to become pregnant, or to breastfeed during the study.
Vulnerable Population
Vulnerable population selected: the trial includes minors/adolescents. Pediatric-specific consent and assent procedures are provided (Pediatric Consent 12-17, Pediatric Assent forms for 11-14 and 15-17, Parental/Parental ICFs). Parental/guardian consent is required for minors with age-appropriate assent; dedicated parental and pediatric information and consent/assent forms are provided and available in multiple country-specific versions.

Inclusion criteria

  • {"criterion_text":"- 1. Physician-diagnosed chronic rhinosinusitis (CRS) with bilateral nasal polyps (NP)."}
  • {"criterion_text":"- 2. Prior treatment with systemic corticosteroids (SCS) for CRS or CRSwNP within the last 2 years (or a medical contraindication or intolerance to SCS), prior surgery for NP, or both."}
  • {"criterion_text":"- 3. Endoscopic bilateral NPS score of at least 5 out of 8, with a minimum score of 2 in each nasal cavity performed at screening and baseline."}
  • {"criterion_text":"- 4. Ongoing symptoms for at least 8 weeks prior to study entry (screening), including: a. Nasal congestion with moderate or severe symptom severity (score 2 or 3) at screening and a weekly average severity score of at least 1 (range 0 to 3) at randomization, and b. At least one other symptom, such as, but not limited to, partial loss of smell (hyposmia), total loss of smell (anosmia), or anterior or posterior rhinorrhea."}
  • {"criterion_text":"- 4.a. Nasal congestion with moderate or severe symptom severity (score 2 or 3) at screening and a weekly average severity score of at least 1 (range 0 to 3) at randomization."}
  • {"criterion_text":"- 4.b. At least one other symptom, such as, but not limited to, partial loss of smell (hyposmia), total loss of smell (anosmia), or anterior or posterior rhinorrhea."}
  • {"criterion_text":"- 5. Patients who have concomitant asthma must be stable in the 3 months prior to screening using permitted regular asthma treatment."}

Exclusion criteria

  • {"criterion_text":"- 1. Have received a dose of lebrikizumab."}
  • {"criterion_text":"- 2. Have received treatment with any rescue medication and/or have the need for surgery for NP during screening and/or run-in period."}
  • {"criterion_text":"- 3. Allergen immunotherapy (subcutaneous immunotherapy [SCIT]/sublingual immunotherapy [SLIT]) initiated within 6 months prior to screening, that is not on a stable dose (3 months prior to screening) or may require a dose change during study."}
  • {"criterion_text":"- 4. Prior or current biologic treatment for CRSwNP and/or asthma and/or atopic dermatitis (AD), including but not limited to omalizumab, dupilumab, mepolizumab, reslizumab, and benralizumab."}
  • {"criterion_text":"- 5. Have received treatment with any biologic or systemic immunosuppressants for inflammatory disease or autoimmune disease prior to the baseline visit:"}
  • {"criterion_text":"- 5.a. B cell-depleting biologics, including rituximab, within 6 months."}
  • {"criterion_text":"- 5.b. other biologics within 5 half-lives (if known) or 8 weeks, whichever is longer."}
  • {"criterion_text":"- 5.c. Systemic immunosuppressants within 4 weeks prior to baseline."}
  • {"criterion_text":"- 6. Have had any sinus intranasal surgery (including nasal polypectomy) within 6 months prior to screening"}
  • {"criterion_text":"- 7. Have had prior sino-nasal surgery or sinus surgery changing lateral wall structure of the nose making it difficult to assess endoscopic NPS"}
  • {"criterion_text":"- 8. Have a presence of any of the following conditions that may impact the assessment of endpoints at screening or baseline:"}
  • {"criterion_text":"- 8.a. Nasal septal deviation occluding at least one nostril."}
  • {"criterion_text":"- 8.b. Antrochoanal polyps."}
  • {"criterion_text":"- 8.c. Acute sinusitis, acute nasal infection, or acute upper respiratory infection."}
  • {"criterion_text":"- 8.d. Ongoing rhinitis medicamentosa."}
  • {"criterion_text":"- 8.e. Presence of another diagnosis associated with NP (ie, eosinophilic granulomatosis with polyangiitis, granulomatosis with polyangiitis, Young’s syndrome, primary ciliary dyskinesia, cystic fibrosis)."}
  • {"criterion_text":"- 8.f. A nasal cavity tumor (malignant or benign)."}
  • {"criterion_text":"- 8.g. Evidence of fungal rhinosinusitis."}
  • {"criterion_text":"- 9. Have anosmia from COVID or any reason other than CRSwNP."}
  • {"criterion_text":"- 10. Participants with forced expiratory volume in 1 second (FEV1) 50% or less (of predicted normal) at screening."}
  • {"criterion_text":"- 11. Female participant who is pregnant, breastfeeding, or is planning to become pregnant, or to breastfeed during the study."}

Endpoints

Primary endpoints

  • {"endpoint_text":"- 1. Mean Change From Baseline (CFBL) in Participant Reported Nasal Congestion Score (NCS) Severity","definition_or_measurement_approach":"Participant-reported Nasal Congestion Score (NCS) severity recorded by study participants using a 4-point scale (0-3) in the participant eDiary; Time Frame: Baseline, Week 24."}
  • {"endpoint_text":"- NCS severity is rated by study participants using a 4-point scale (range from 0 to 3), where 0 corresponds to no symptoms and 3 corresponds to severe symptoms. Study participants are asked to record the severity of nasal congestion for the previous 24 hours. This assessment will be collected in the participant eDiary. [Time Frame: Baseline, Week 24]","definition_or_measurement_approach":"NCS: 4-point scale (0=no symptoms, 3=severe); participants record prior 24 hours in eDiary. Time points: Baseline and Week 24."}
  • {"endpoint_text":"- 2. Mean CFBL in Endoscopic Nasal Polyp Score (NPS)","definition_or_measurement_approach":"Endoscopic NPS assessed by centralized, blinded, independent review of nasal endoscopy video recordings. Total score is sum of right and left nasal cavity scores; each cavity graded 0-4 based on polyp size. [Time Frame: Baseline, Week 24]"}

Recruitment

Digital Remote Recruitment
Yes
Planned Sample Size
748
Recruitment Window Months
41
Consent Approach
Informed consent is obtained using country- and population-specific ICFs. For adults the Main ICF is used; for minors pediatric consent (12-17) and pediatric assent forms (11-14, 15-17) plus Parental/Parental ICFs are provided. Additional ICFs include pregnant partner ICFs and optional sub-study ICFs. Consent/assent materials are provided in multiple country/language versions (country-specific ICF documents listed for ES, DE, IT, BE, PL, RO, PT, HU, BG, etc.).

Methods

  • Social media advertisements (assets: Social_1080x1080, Social_1200x628, Social-Media-Ads) — country-specific versions available (e.g., ES, DE, BE, IT, PL, RO, BG, PT, HU). Target: patients with CRSwNP / general public likely to have symptoms.
  • Landing pages / URLs (SS_Landing Page, SYN_Landing Page) — country-specific landing pages to capture interest and direct potential participants to screening (several language/country versions present).
  • Patient letters and GP/Doctor-to-Patient letters — to inform and recruit patients via healthcare providers (country-specific patient letters present for ES, BE, IT, DK, RO, PT, PL, HU, BG, etc.).
  • Posters, flipcharts, recruitment brochures — printed/study-team materials for clinic and community recruitment (country-specific posters and brochures).
  • Patient referral questionnaire and AES Patient Referral Questionnaires — tools to capture patient referrals and pre-screening information.
  • Keyword search / online ads (SS_KEYWORD-SEARCH) and URLs — digital outreach via search-targeted advertising.
  • Video ICF and other multimedia information — used in some countries to inform participants.
  • Study site outreach (clinic-based recruitment) — site lists show otorhinolaryngology/ENT departments and allergy clinics as recruitment venues.

Geography

Total Number Of Sites
63
Total Number Of Participants
272

Spain

Earliest CTIS Part Ii Submission Date
17-06-2024
Latest Decision Or Authorization Date
06-03-2026
Processing Time Days
627
Number Of Sites
9
Number Of Participants
45

Sites

Site Name
Centro Medico Teknon-Grupo Quironsalud
Department Name
Otorhinolaryngology
Contact Person Name
Isam Alobid
Contact Person Email
ialobid@clinic.cat
Site Name
Hospital Universitario Fundacion Jimenez Diaz
Department Name
Otorhinolaryngology
Contact Person Name
Jose Villacampa
Contact Person Email
jmvillacampa@fjd.es
Site Name
Hospital Universitario Virgen De La Macarena
Department Name
Otorhinolaryngology
Contact Person Name
Serafin Sanchez Gomez
Site Name
Futuremeds Spain S.L.
Department Name
Allergy
Contact Person Name
Carolina Alfonso Carrillo
Site Name
Hospital Sant Joan De Deu Barcelona
Department Name
Department of Otorhinolaryngology
Contact Person Name
Cristobal Langdon Montero
Contact Person Email
cristobal.langdon@sjd.es
Site Name
Hospital De Jerez De La Frontera
Department Name
Rhinology & Asthma Unit. ENT Department.
Contact Person Name
Alfonso Del Cuvillo
Contact Person Email
dr.cuvillo@comcadiz.es
Site Name
Complexo Hospitalario Universitario De Santiago
Department Name
Otorhinolaryngology
Contact Person Name
Gabriel Martinez Capoccioni
Site Name
Clinica Universidad De Navarra
Department Name
Allergy
Contact Person Name
Gabriel Gastaminza Lasarte
Contact Person Email
gastaminza@unav.es
Site Name
Hospital Universitario Fundacion Jimenez Diaz (additional listing)
Department Name
Otorhinolaryngology

Hungary

Earliest CTIS Part Ii Submission Date
04-08-2025
Latest Decision Or Authorization Date
13-02-2026
Processing Time Days
193
Number Of Sites
3
Number Of Participants
7

Sites

Site Name
Komarom-Esztergom Varmegyei Szent Borbala Korhaz
Department Name
Otolaringology
Contact Person Name
Irma Lehőcz
Contact Person Email
lehoczirma.study@gmail.com
Site Name
Ujpesti Egeszsegkoezpont
Contact Person Name
Attila Velich
Contact Person Email
velichattila@gmail.com
Site Name
Rhinoto Kft.
Contact Person Name
László Lujber
Contact Person Email
lujber@yahoo.com

Belgium

Earliest CTIS Part Ii Submission Date
03-07-2024
Latest Decision Or Authorization Date
12-02-2026
Processing Time Days
589
Number Of Sites
3
Number Of Participants
8

Sites

Site Name
Cliniques Universitaires Saint-Luc
Department Name
Otorhinolaryngology Department
Contact Person Name
Valérie Hox
Contact Person Email
valerie.hox@uclouvain.be
Site Name
Pneumocare
Contact Person Name
Jean Benoit Martinot
Contact Person Email
martinot.j@scralet.be
Site Name
Universitair Ziekenhuis Gent
Department Name
Otorhinolaryngology Department
Contact Person Name
Philippe Gevaert
Contact Person Email
philippe.gevaert@uzgent.be

Germany

Earliest CTIS Part Ii Submission Date
18-07-2024
Latest Decision Or Authorization Date
12-02-2026
Processing Time Days
574
Number Of Sites
8
Number Of Participants
39

Sites

Site Name
Technische Universitaet Dresden
Department Name
Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde
Contact Person Name
Philipp Nahrath
Contact Person Email
philipp.nahrath@ukdd.de
Site Name
IKF Pneumologie GmbH & Co. KG
Department Name
N/A - Additional streetname as site is located at a corner: Stresemannallee 3
Contact Person Name
Marc Oliver Kornmann
Contact Person Email
kornmann@ikf-pneumologie.de
Site Name
HNO Praxis Dresden Dr. med. Udo Schäfer
Contact Person Name
Udo Schäfer
Contact Person Email
schaefer@hno-praxis-dresden.de
Site Name
Charite Universitaetsmedizin Berlin KöR
Department Name
Klinik für Hals-, Nasen-, Ohrenheilkunde
Contact Person Name
Heidi Olze
Contact Person Email
heidi.olze@charite.de
Site Name
Praxis für HNO und Allergologie Dr. Yury Yarin
Contact Person Name
Yury Yarin
Contact Person Email
dr.yarin@googlemail.com
Site Name
Universitaetsklinikum Jena KöR
Department Name
Klinik für Hals-, Nasen- und Ohrenheilkunde
Contact Person Name
Orlando Guntinas-Lichius
Site Name
HNO Zentrum am Kudamm
Contact Person Name
Önder Göktas
Contact Person Email
goektas@hnozentrum-kudamm.de
Site Name
Universitaetsklinikum Schleswig-Holstein AöR
Department Name
Sektion für Hals-, Nasen- und Ohrenheilkunde
Contact Person Name
Anke Leichtle
Contact Person Email
anke.leichtle@uksh.de

Italy

Earliest CTIS Part Ii Submission Date
17-07-2024
Latest Decision Or Authorization Date
12-02-2026
Processing Time Days
575
Number Of Sites
8
Number Of Participants
20

Sites

Site Name
Azienda Ospedaliero Universitaria Pisana
Department Name
UO Otorinolaringoiatria, Audiologia e Foniatria Universitaria
Contact Person Name
Veronica Seccia
Contact Person Email
v.seccia@ao-pisa.toscana.it
Site Name
Azienda Ospedaliera Universitaria Federico II Di Napoli
Department Name
Internal Medicine and Clinical Complexities
Contact Person Name
Aikaterini Detoraki
Contact Person Email
aikaterini.detoraki@unina.it
Site Name
Azienda Ospedaliera di Padova
Department Name
Neurosciences DNS
Contact Person Name
Giancarlo Ottaviano
Contact Person Email
giancarlo.ottaviano@unipd.it
Site Name
Azienda Ospedaliera Universitaria Senese
Department Name
UOC Otorinolaringoiatria
Contact Person Name
Marco Mandalà
Contact Person Email
marco.mandala@unisi.it
Site Name
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Department Name
UOC Otorinolaringoiatria
Contact Person Name
Eugenio De Corso
Site Name
Azienda Socio Sanitaria Territoriale Della Brianza
Department Name
UOC Otorinolaringoiatria
Contact Person Name
Federico Giuseppe Quarta
Site Name
Ospedale San Raffaele S.r.l.
Department Name
Unità Operativa di Otorinolaringoiatria
Contact Person Name
Giulia Dané
Contact Person Email
dane.giulia@hsr.it
Site Name
Careggi University Hospital
Department Name
Experimental and Clinical Medicine
Contact Person Name
Alessandra Vultaggio
Contact Person Email
alessandra.vultaggio@unifi.it

Denmark

Earliest CTIS Part Ii Submission Date
05-07-2024
Latest Decision Or Authorization Date
09-02-2026
Processing Time Days
584
Number Of Sites
3
Number Of Participants
15

Sites

Site Name
Region Sjaelland
Department Name
Oere-Naese-Hals og Kaebekirurgisk Afdeling
Contact Person Name
Preben Homoee
Contact Person Email
prho@regionsjaelland.dk
Site Name
Aalborg University Hospital
Department Name
Department of Respiratory Diseases
Contact Person Name
Ulla Weinreich
Contact Person Email
ulw@rm.dk
Site Name
Aarhus Universitetshospital
Department Name
Department of Ear-Nose-Throat
Contact Person Name
Teis Ehlers Klug
Contact Person Email
tejsklug@rm.dk

Romania

Earliest CTIS Part Ii Submission Date
29-04-2024
Latest Decision Or Authorization Date
16-02-2026
Processing Time Days
658
Number Of Sites
7
Number Of Participants
38

Sites

Site Name
Delta Health Care S.R.L.
Department Name
Departament Otorinolaringologie (ORL)
Contact Person Name
Corina-Camelia Mella
Contact Person Email
corinamella@yahoo.com
Site Name
Delta Health Care S.R.L. (second listing)
Department Name
Departament Otorinolaringologie (ORL)
Contact Person Name
Jana-Sorina Dindere
Contact Person Email
sorina.dindere@reginamaria.ro
Site Name
Centrul Medical Unirea S.R.L.
Department Name
Department Otorinolaringologie
Contact Person Name
Catalin Stefan
Contact Person Email
drcatalinstefan@gmail.com
Site Name
Cardiomed S.R.L.
Department Name
Departament Otorinolaringologie (ORL)
Contact Person Name
Gheorghe-Doinel Radeanu
Contact Person Email
doinelra@yahoo.com
Site Name
Centrul De Excelenta In Rinologie S.R.L.
Department Name
Department Otorinolaringologie
Contact Person Name
Mihaela-Roxana Mitroi
Contact Person Email
mhlmitroi@yahoo.com
Site Name
Centrul Medical De Diagnostic Si Tratament Ambulator Neomed S.R.L.
Department Name
Department Otorinolaringologie (ORL)
Contact Person Name
Valeriu Bronescu
Contact Person Email
bronescu@neomed.org
Site Name
Centrul Medical De Diagnostic Si Tratament Ambulator Neomed S.R.L. (second listing)
Department Name
Department Otorinolaringologie (ORL)
Contact Person Name
Anemone-Sorana Lupescu
Contact Person Email
anemone@neomed.org

Bulgaria

Earliest CTIS Part Ii Submission Date
04-07-2024
Latest Decision Or Authorization Date
10-02-2026
Processing Time Days
586
Number Of Sites
5
Number Of Participants
27

Sites

Site Name
Medical Center Medconsult Pleven OOD
Contact Person Name
Georgi Nikolov
Contact Person Email
nikolov_medconsult@abv.bg
Site Name
Multiprofile Hospital For Active Treatment Dr. Tota Venkova AD
Department Name
Ear, nose and throat department
Contact Person Name
Dimitar Dimitrov
Contact Person Email
dr.dimitrovv@gmail.com
Site Name
Uniteversity Muliprofile Hospital For Active Treatment Tsaritsa Yoanna-Isul EAD
Department Name
Ear, nose and throat Clinic
Contact Person Name
Yulian Rangachev
Contact Person Email
rangachev@abv.bg
Site Name
Diagnostic Consultative Centre Ascendent EOOD
Contact Person Name
Emiliya Yordanova
Site Name
Military Medical Academy
Department Name
Ear, nose and throat Clinic
Contact Person Name
Ventzislav Tzvetkov
Contact Person Email
vtcvetkov@yahoo.com

Poland

Earliest CTIS Part Ii Submission Date
03-07-2024
Latest Decision Or Authorization Date
16-02-2026
Processing Time Days
593
Number Of Sites
11
Number Of Participants
51

Sites

Site Name
Centrum Medyczne All-Med Badania Kliniczne
Contact Person Name
Grażyna Pulka
Contact Person Email
pulkaallmed@gmail.com
Site Name
Niepubliczny Zakład Opieki Zdrowotnej EVita
Contact Person Name
Ewa Michnowska-Tryburska
Contact Person Email
drewam@o2.pl
Site Name
Centrum Medyczne Oporow
Contact Person Name
Yogen Abelak
Contact Person Email
yogen@abelak.com
Site Name
Centrum Medyczne Angelius Provita
Contact Person Name
Tomasz Grzegorzek
Contact Person Email
t.grzegorzek@angelius.org
Site Name
Specjalistyczny Niepubliczny Zaklad Opieki Zdrowotnej Alergologia Plus Osrodek Diagnostyki I Terapii Uczulen
Contact Person Name
Michał Springer
Contact Person Email
michal.springer.pl@gmail.com
Site Name
Centrum Medyczne Biotamed Morawska Barbara
Contact Person Name
Piotr Morawski
Contact Person Email
morawscy@op.pl
Site Name
Centrum Medyczne Pratia Katowice
Contact Person Name
Santa Vanaga-Besser
Contact Person Email
svbesser.pratia@gmail.com
Site Name
EMC Instytut Medyczny S.A. Przychodnia EuroMediCare, Wrocław Łowiecka
Contact Person Name
Marita Nittner-Marszalska
Site Name
B&R Clinical Sp. z o.o.
Contact Person Name
Marcin Zawadzki
Contact Person Email
marcin.zawadzki@brclinical.pl
Site Name
Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy
Contact Person Name
Dariusz Jurkiewicz
Contact Person Email
djurkiewicz@wim.mil.p
Site Name
Centrum Medyczne PROMED
Contact Person Name
Piotr Łach
Contact Person Email
badania.kliniczne@cmpromed.pl

Portugal

Earliest CTIS Part Ii Submission Date
05-09-2025
Latest Decision Or Authorization Date
13-02-2026
Processing Time Days
161
Number Of Sites
6
Number Of Participants
22

Sites

Site Name
Unidade Local De Saude De Loures-Odivelas EPE
Department Name
Otorhinolaryngology Department
Contact Person Name
Luís Rodrigues
Contact Person Email
luisrodrigues@gmail.com
Site Name
Unidade Local De Saude De Almada-Seixal E.P.E.
Department Name
Otorhinolaryngology Department
Contact Person Name
Luís Antunes
Contact Person Email
lantunes@ulsas.min-saude.pt
Site Name
Unidade Local De Saude De Matosinhos E.P.E.
Department Name
Otorhinolaryngology Service
Contact Person Name
Miguel Viana
Contact Person Email
miguel.viana@ulsm.min-saude.pt
Site Name
Unidade Local De Saude Do Algarve E.P.E.
Department Name
Otorhinolaryngology Unit
Contact Person Name
Natacha Santos
Site Name
Unidade Local De Saude Da Regiao De Aveiro E.P.E.
Department Name
Otorhinolaryngology Service
Contact Person Name
Maria Luísa Azevedo
Site Name
CCAB Centro Clinico Academico Braga Associacao
Department Name
Otorhinolaryngology Service
Contact Person Name
Daniel Miranda
Contact Person Email
jose.miranda@ulsb.min-saude.pt

Sponsor

Primary sponsor

Full Name
Eli Lilly & Co.
Organisation Type
Pharmaceutical company
Country Of Registered Address
United States

Contract research organisations

Name
Wuxi Apptec Co. Ltd.
Name
PPD Development LP
Name
Labcorp Pharmaceutical Research And Development (Shanghai) Co. Ltd.
Name
Labcorp Early Development Laboratories Inc.
Name
PPD Global Central Labs
Name
Q Squared Solutions LLC
Name
eResearchTechnology GmbH
Name
Clinical Ink Inc.

Third parties

  • {"country":"China","full_name":"Wuxi Apptec Co. Ltd.","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
  • {"country":"Germany","full_name":"eResearchTechnology GmbH","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Clinical Ink Inc.","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
  • {"country":"China","full_name":"Labcorp Pharmaceutical Research And Development (Shanghai) Co. Ltd.","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Q Squared Solutions LLC","duties_or_roles":"","organisation_type":"Laboratory/Research/Testing facility"}
  • {"country":"United States","full_name":"PPD Development LP","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Labcorp Early Development Laboratories Inc.","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
  • {"country":"Belgium","full_name":"PPD Global Central Labs","duties_or_roles":"","organisation_type":"Pharmaceutical company"}

Investigational products

Investigational Product Name
Lebrikizumab
Active Substance
LEBRIKIZUMAB
Modality
Monoclonal antibody
Routes Of Administration
Subcutaneous injection
Route
Subcutaneous injection
Investigational Product Name
Placebo for Lebrikizumab
Modality
Other
Investigational Product Name
MOMETASONE
Active Substance
MOMETASONE FUROATE
Modality
Small molecule
Routes Of Administration
Nasal spray
Route
Nasal spray
Combination Treatment
Yes

Related trials

Other published trials that may interest you.